DE102017114737A1 - Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie - Google Patents

Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie Download PDF

Info

Publication number
DE102017114737A1
DE102017114737A1 DE102017114737.3A DE102017114737A DE102017114737A1 DE 102017114737 A1 DE102017114737 A1 DE 102017114737A1 DE 102017114737 A DE102017114737 A DE 102017114737A DE 102017114737 A1 DE102017114737 A1 DE 102017114737A1
Authority
DE
Germany
Prior art keywords
seq
tcr
antigen
chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102017114737.3A
Other languages
German (de)
English (en)
Inventor
Claudia Wagner
Leonie ALTEN
Sebastian Bunk
Dominik Maurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to DE102017114737.3A priority Critical patent/DE102017114737A1/de
Priority to PE2019002620A priority patent/PE20200337A1/es
Priority to SG11201911437VA priority patent/SG11201911437VA/en
Priority to CA3067757A priority patent/CA3067757A1/en
Priority to CN201880033171.0A priority patent/CN110753705A/zh
Priority to PH1/2019/502847A priority patent/PH12019502847A1/en
Priority to TW107122290A priority patent/TWI727182B/zh
Priority to MYPI2019007601A priority patent/MY205262A/en
Priority to MA049503A priority patent/MA49503A/fr
Priority to AU2018293322A priority patent/AU2018293322A1/en
Priority to EP18737546.4A priority patent/EP3645573B1/en
Priority to MX2019015742A priority patent/MX2019015742A/es
Priority to CR20190594A priority patent/CR20190594A/es
Priority to KR1020197036902A priority patent/KR20200023288A/ko
Priority to JP2019569676A priority patent/JP7235316B2/ja
Priority to BR112019025323-8A priority patent/BR112019025323A2/pt
Priority to PCT/EP2018/067380 priority patent/WO2019002444A1/en
Priority to ARP180101832 priority patent/AR112604A1/es
Priority to US16/023,731 priority patent/US10590194B2/en
Publication of DE102017114737A1 publication Critical patent/DE102017114737A1/de
Priority to US16/403,269 priority patent/US10723796B2/en
Priority to CL2019003885A priority patent/CL2019003885A1/es
Priority to IL271751A priority patent/IL271751A/en
Priority to US16/733,845 priority patent/US11111294B2/en
Priority to CONC2020/0000357A priority patent/CO2020000357A2/es
Priority to US17/397,656 priority patent/US20210388079A1/en
Priority to US18/916,878 priority patent/US20250154246A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE102017114737.3A 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie Withdrawn DE102017114737A1 (de)

Priority Applications (26)

Application Number Priority Date Filing Date Title
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
JP2019569676A JP7235316B2 (ja) 2017-06-30 2018-06-28 新規ｔ細胞受容体およびそれを用いた免疫療法
KR1020197036902A KR20200023288A (ko) 2017-06-30 2018-06-28 신규 t 세포 수용체 및 이를 사용하는 면역 요법
CA3067757A CA3067757A1 (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same
CN201880033171.0A CN110753705A (zh) 2017-06-30 2018-06-28 新型t细胞受体及其免疫治疗
PH1/2019/502847A PH12019502847A1 (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same
TW107122290A TWI727182B (zh) 2017-06-30 2018-06-28 新型t細胞受體及其免疫治療
MYPI2019007601A MY205262A (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same
MA049503A MA49503A (fr) 2017-06-30 2018-06-28 Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
AU2018293322A AU2018293322A1 (en) 2017-06-30 2018-06-28 Novel T cell receptors and immune therapy using the same
SG11201911437VA SG11201911437VA (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same
MX2019015742A MX2019015742A (es) 2017-06-30 2018-06-28 Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
BR112019025323-8A BR112019025323A2 (pt) 2017-06-30 2018-06-28 Receptores de células t e imunoterapia empregando os mesmos
PE2019002620A PE20200337A1 (es) 2017-06-30 2018-06-28 Receptores de celulas t novedosos, e inmunoterapia usando los mismos
EP18737546.4A EP3645573B1 (en) 2017-06-30 2018-06-28 Novel t cell receptors and immune therapy using the same
CR20190594A CR20190594A (es) 2017-06-30 2018-06-28 Receptores de células t novedosos, e inmunoterapia usando los mismos
PCT/EP2018/067380 WO2019002444A1 (en) 2017-06-30 2018-06-28 NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
ARP180101832 AR112604A1 (es) 2017-06-30 2018-06-29 Receptores de células t, e inmunoterapia usando los mismos
US16/023,731 US10590194B2 (en) 2017-06-30 2018-06-29 T cell receptors and immune therapy using the same
US16/403,269 US10723796B2 (en) 2017-06-30 2019-05-03 T cell receptors and immune therapy using the same
CL2019003885A CL2019003885A1 (es) 2017-06-30 2019-12-27 Receptores de células t novedosos, e inmunoterapia usando los mismos.
IL271751A IL271751A (en) 2017-06-30 2019-12-29 T cell receptors and immunotherapy using them
US16/733,845 US11111294B2 (en) 2017-06-30 2020-01-03 T cell receptors and immune therapy using the same
CONC2020/0000357A CO2020000357A2 (es) 2017-06-30 2020-01-14 Receptores de células t novedosos, e inmunoterapia usando los mismos
US17/397,656 US20210388079A1 (en) 2017-06-30 2021-08-09 Novel t cell receptors and immune therapy using the same
US18/916,878 US20250154246A1 (en) 2017-06-30 2024-10-16 Novel t cell receptors and immune therapy using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Publications (1)

Publication Number Publication Date
DE102017114737A1 true DE102017114737A1 (de) 2019-01-03

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102017114737.3A Withdrawn DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Country Status (22)

Country Link
US (5) US10590194B2 (https=)
EP (1) EP3645573B1 (https=)
JP (1) JP7235316B2 (https=)
KR (1) KR20200023288A (https=)
CN (1) CN110753705A (https=)
AR (1) AR112604A1 (https=)
AU (1) AU2018293322A1 (https=)
BR (1) BR112019025323A2 (https=)
CA (1) CA3067757A1 (https=)
CL (1) CL2019003885A1 (https=)
CO (1) CO2020000357A2 (https=)
CR (1) CR20190594A (https=)
DE (1) DE102017114737A1 (https=)
IL (1) IL271751A (https=)
MA (1) MA49503A (https=)
MX (1) MX2019015742A (https=)
MY (1) MY205262A (https=)
PE (1) PE20200337A1 (https=)
PH (1) PH12019502847A1 (https=)
SG (1) SG11201911437VA (https=)
TW (1) TWI727182B (https=)
WO (1) WO2019002444A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025006196A1 (en) * 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230343A1 (es) 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5244499A (en) * 1998-07-31 2000-02-21 Diagnostic Products Corporation Polynucleotide encoding an autoantigen associated with endometriosis
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
US10550154B2 (en) * 2012-08-08 2020-02-04 Daiichi Sankyo Company, Limited Peptide library and use thereof
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
US10066002B2 (en) * 2014-11-05 2018-09-04 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
1. Internet Recherche vom 20.03.2018 www.ncbi.nlm.nih.gov/protein NP_001258647 *
2. K. E. TILLER und P. M. TESSIER: Advances in antibody design. 2015. Annual review of biomedical engineering, Vol. 17, S. 191-216 *
C.A. Janeway et al. (eds.), Immunobiology, 8 Ed., Garland Publishing, New York, NY (201 1)
Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988)
Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), und Roder et al, Methods Enzymol, 121, 140-67 (1986)
Huse et al., Science, 246, 1275-81 (1989)
Kohler and Milstein, Eur. J. Immunol, 5, 51 1-519 (1976)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025006196A1 (en) * 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Also Published As

Publication number Publication date
EP3645573B1 (en) 2024-10-16
BR112019025323A2 (pt) 2020-06-23
EP3645573A1 (en) 2020-05-06
AU2018293322A1 (en) 2020-01-16
IL271751A (en) 2020-02-27
TW201904989A (zh) 2019-02-01
TWI727182B (zh) 2021-05-11
US20250154246A1 (en) 2025-05-15
US20190002556A1 (en) 2019-01-03
US20190256590A1 (en) 2019-08-22
CR20190594A (es) 2020-03-02
JP7235316B2 (ja) 2023-03-08
KR20200023288A (ko) 2020-03-04
AR112604A1 (es) 2019-11-20
PH12019502847A1 (en) 2020-10-26
US20200140540A1 (en) 2020-05-07
WO2019002444A9 (en) 2019-03-14
US10723796B2 (en) 2020-07-28
CL2019003885A1 (es) 2020-05-29
MY205262A (en) 2024-10-10
MA49503A (fr) 2020-05-06
US11111294B2 (en) 2021-09-07
WO2019002444A1 (en) 2019-01-03
US20210388079A1 (en) 2021-12-16
CO2020000357A2 (es) 2020-01-31
CA3067757A1 (en) 2019-01-03
PE20200337A1 (es) 2020-02-14
US10590194B2 (en) 2020-03-17
MX2019015742A (es) 2020-02-20
SG11201911437VA (en) 2020-01-30
JP2020529830A (ja) 2020-10-15
CN110753705A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
DE102016123847B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123859B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016115246B3 (de) Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102017114737A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102017106305A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
JP7787119B2 (ja) Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法
US20240285779A1 (en) Novel t cell receptors and immune therapy using the same
DE102017125888A1 (de) Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
HK40078003A (en) Novel t cell receptors and immune therapy using the same
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40014640A (en) Novel t cell receptors and immune therapy using the same
HK40014640B (en) Novel t cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R082 Change of representative

Representative=s name: ZSP PATENTANWAELTE PARTG MBB, DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R016 Response to examination communication
R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee